Home / Mesothelioma / Stages
Mesothelioma Stages: What Stages 1–4 Mean
After a mesothelioma diagnosis, patients and families often want to know the disease stage. The stage describes how much cancer is present and how far it has spread at the time of evaluation.
Diffuse pleural mesothelioma, which develops in the pleura, the thin membrane that lines the inside of the chest wall and covers the lungs, is classified into four main stages. Stage 1 is the most localized. Stages 2 and 3 reflect increasing local spread or lymph node involvement. Stage 4 indicates the cancer has reached distant organs or tissues.
Staging offers critical information regarding disease extent, but it does not predict individual outcomes. Treatment and prognosis also depend on tumor subtype, anatomical location, surgical options, overall health, and response to therapy.
Throughout this guide, the term “pleural mesothelioma” refers to diffuse pleural mesothelioma unless otherwise specified. The AJCC TNM staging system described below was developed for diffuse pleural disease and is not directly applicable to localized pleural mesothelioma.
Symptoms alone are insufficient to determine the stage of mesothelioma. Physicians utilize imaging, biopsy results, lymph node evaluation, and, in some cases, surgical findings to assign a stage.
Table of Contents
- The Four Stages
- Stage Comparison Table
- The TNM System
- AJCC Version 9 Changes
- Clinical vs. Pathological Stage
- Stage 1
- Stage 2
- Stage 3
- Stage 4
- Early vs. Advanced
- How Doctors Determine Stage
- Resectable vs. Unresectable
- How Stage Affects Treatment
- Staging Other Types
- Stage vs. Grade and Prognosis
- Can Stage Change?
- Questions to Ask
- FAQ
- References
Key Takeaways
- Pleural mesothelioma is divided into four principal stages, from Stage 1 through Stage 4.
- The current AJCC system uses the TNM framework: tumor extent, lymph-node involvement, and distant metastasis.
- Pleural mesothelioma is the only major mesothelioma type with a widely established formal TNM staging system.
- Earlier-stage disease is generally more localized, but stage alone does not determine whether surgery is appropriate.
- Stage is only one part of prognosis. Cell type, overall health, treatment response, and other clinical factors also matter.
- Palliative care may be provided at any stage and does not mean that a patient is entering hospice.
What Are the Four Stages of Mesothelioma?
Pleural mesothelioma is grouped into four main stages.
- Stage 1: The cancer is localized to the pleura on one side of the chest. It has not spread to lymph nodes or distant organs.
- Stage 2: The cancer has become more extensive within the same side of the chest or has reached certain nearby lymph nodes, but it has not spread to distant organs.
- Stage 3: The cancer is more locally advanced, may involve regional lymph nodes, and may have grown into nearby chest structures. It has not produced distant metastasis.
- Stage 4: The cancer has spread to a distant part of the body.
These descriptions are simplified. A specialist determines the exact stage by assessing the tumor, lymph nodes, imaging, and evidence of distant spread.
Mesothelioma Stage Comparison
| Stage | General Extent of Disease | Lymph-Node Involvement | Distant Spread | Common Treatment-Planning Focus |
|---|---|---|---|---|
| Stage 1 | Localized to the pleura on one side of the chest | No | No | Assessment for surgery or multimodal treatment in selected patients |
| Stage 2 | More extensive local disease or limited nearby node involvement | None or limited regional involvement | No | Multidisciplinary evaluation, with surgery considered in selected cases |
| Stage 3 | Advanced local or regional disease | May involve same-side, opposite-side, or supraclavicular nodes, depending on the subgroup | No | Systemic treatment, multidisciplinary assessment, symptom control, and surgery only in carefully selected cases |
| Stage 4 | Metastatic disease | May or may not be present | Yes | Systemic therapy, clinical trials, symptom-directed treatment, and supportive or palliative care |
Treatment decisions are not based solely on stage. The care team also considers resectability, cell type, functional status, heart and lung function, previous treatments, and patient preferences.
What Does Cancer Staging Mean?
Cancer staging is the process of determining how much cancer is present and where it is located.
For mesothelioma, staging helps answer questions such as:
- How much of the pleura is involved?
- How thick or extensive is the pleural tumor?
- Has the tumor reached nearby chest structures?
- Are regional lymph nodes involved?
- Has the cancer spread to a distant organ or body cavity?
- Could complete removal of all visible tumor be technically possible?
- Which treatments should the multidisciplinary team discuss?
Doctors also use staging to communicate consistently with one another. A thoracic surgeon, medical oncologist, radiation oncologist, radiologist, pulmonologist, and pathologist can use the same classification when reviewing the case.
Staging helps researchers compare patients in clinical studies, but it does not fully summarize an individual diagnosis.
The Current TNM System for Pleural Mesothelioma
The American Joint Committee on Cancer staging system classifies diffuse pleural mesothelioma using three components:
Primary Tumor
Describes the extent of the main pleural tumor.
Considers tumor thickness (Psum), fissure involvement, and invasion of nearby chest structures such as the chest wall, diaphragm, pericardium, or mediastinum.
Regional Lymph Nodes
Describes whether mesothelioma cells have reached regional lymph nodes.
Same-side node involvement is classified differently from opposite-side or supraclavicular node involvement.
Distant Metastasis
Describes whether mesothelioma has spread to a distant site.
May include a distant organ, bone, the opposite lung or pleural cavity, the lining of the abdomen, or lymph nodes outside the regional drainage area.
T: Primary Tumor
The T category describes the extent of the main tumor.
It considers factors such as:
- The amount and thickness of pleural tumor
- Whether the tumor involves the fissures between the lung lobes
- Whether it has grown into nearby tissues
- Whether it has reached the chest wall, diaphragm, pericardium, mediastinum, or other structures
- Whether the tumor has invaded structures that meet the anatomical criteria for T4 disease
TNM stage helps inform whether surgery may be considered, but it does not determine surgical candidacy by itself. Resectability is assessed separately by a multidisciplinary team based on tumor distribution, lymph-node involvement, histological subtype, cardiopulmonary fitness, overall health, and surgical expertise.
N: Regional Lymph Nodes
The N category describes whether mesothelioma cells have reached regional lymph nodes.
The location of the affected nodes matters. Involvement of nodes on the same side of the chest is classified differently from involvement of opposite-side or supraclavicular nodes.
M: Distant Metastasis
The M category describes whether mesothelioma has spread to a distant site.
Examples may include:
- A distant organ
- Bone
- The opposite lung or pleural cavity
- The lining of the abdomen
- Lymph nodes outside the regional drainage area
When distant metastasis is confirmed, the disease is classified as Stage 4.
What Changed in AJCC Version 9?
The current Version 9 system for pleural mesothelioma incorporates revisions developed through the International Association for the Study of Lung Cancer staging project.
One of the principal changes in AJCC Version 9 is the use of an imaging-based measurement called Psum. Psum is calculated by adding pleural tumor thickness measured at three predefined locations on cross-sectional imaging. It helps classify the anatomical extent of the primary tumor but does not measure the total volume of cancer in the chest.
In simplified terms: T1 is Psum 12 mm or less, without fissural involvement. T2 is Psum more than 12 mm but no more than 30 mm, or Psum 12 mm or less with qualifying fissural or limited local involvement. T3 is Psum greater than 30 mm. T4 means the tumor has invaded structures that generally prevent complete surgical removal.
These simplified Psum thresholds are used primarily when assigning the clinical T category from imaging. When surgery provides pathological information, the T category may also be based on direct evidence of tumor involvement in structures such as the fissure, lung tissue, diaphragm, mediastinal fat, endothoracic fascia, pericardium, or chest wall. Clinical and pathological T categories therefore use related but not always identical information.
These measurements must be interpreted alongside fissural involvement and invasion of nearby anatomical structures. Patients should not attempt to determine their own T category from a radiology report without discussing it with their specialist.
Why older sources may look different: Some medical websites and older clinical documents still display AJCC eighth-edition stage descriptions, including subdivisions that differ from Version 9. This article uses the current Version 9 stage groups. Patients reviewing older records should ask which edition was used at the time of diagnosis.
Questions patients can ask their care team: Which edition of the TNM system was used to determine my stage? What are my exact T, N, and M categories, and how were they established? This is especially helpful when reviewing older medical records or seeking a second opinion.
Clinical Stage vs. Pathological Stage
Mesothelioma may have a clinical stage, a pathological stage, or both.
Clinical Stage
The clinical stage is estimated using information available before major surgery.
It may include:
- Physical examination
- CT or PET-CT imaging
- MRI
- Biopsy findings
- Lymph-node sampling
- Thoracoscopy or other diagnostic procedures
The clinical stage is used to guide initial treatment planning.
Pathological Stage
A pathological, or surgical, stage can be assigned when surgery provides additional information about the tumor and lymph nodes.
It combines preoperative findings with what the surgeon and pathologist learn from tissue removed during the operation.
The pathological stage may differ from the clinical stage. Imaging can miss small areas of tumor, and surgery may reveal disease that was not visible on scans.
Not every patient undergoes an operation that allows a complete pathological stage to be assigned.
Jump to a Stage
Stage 1 Pleural Mesothelioma
Stage 1 is the most localized in the current pleural mesothelioma staging system.
TNM Combination
In Version 9, Stage 1 corresponds to T1, N0, M0.
This generally means:
- The tumor is in the pleura on one side of the chest.
- Psum is 12 mm or less, and the tumor does not involve the fissure between the lung lobes.
- No regional lymph-node metastasis has been found.
- No distant metastasis has been found.
Symptoms at Stage 1
Symptoms may be absent, mild, or significant. A localized tumor can still cause substantial breathlessness when pleural fluid accumulates. Symptoms alone cannot distinguish Stage 1 from another stage.
Treatment Planning at Stage 1
Because Stage 1 disease is more localized, the medical team may evaluate whether the patient is a candidate for surgery as part of a multimodal treatment plan.
However, Stage 1 does not guarantee that surgery is possible or recommended. Decisions depend on:
- The exact location and distribution of the tumor
- The mesothelioma cell type
- Heart and lung function
- Functional status
- Other medical conditions
- The experience of the treating center
- The patient’s priorities
Chemotherapy, immunotherapy, radiation therapy, clinical trials, and symptom-directed procedures may also be considered.
Stage 2 Pleural Mesothelioma
Stage 2 pleural mesothelioma remains confined to the chest region and has not spread to distant organs.
TNM Combination
Under Version 9, Stage 2 can include T2, N0, M0, or T1, N1, M0.
This means the local tumor is either more extensive than in Stage 1 without lymph node involvement, or a smaller T1 tumor has reached certain same-side lymph nodes.
The T2 category may include a Psum greater than 12 mm but no more than 30 mm. It may also include a tumor with a lower Psum when there is qualifying fissural involvement or limited invasion of nearby tissues.
Symptoms at Stage 2
Symptoms may include breathlessness, chest discomfort, cough, fatigue, or symptoms caused by pleural fluid. However, these symptoms are nonspecific and cannot distinguish Stage 2 from another stage.
Treatment Planning at Stage 2
Some patients with Stage 2 disease may be evaluated for surgery within a multimodal plan.
The team may also discuss:
- Chemotherapy
- Immunotherapy
- Radiation therapy in selected situations
- Management of pleural fluid
- Pain and breathing support
- Clinical trials
Regional lymph node involvement can affect the expected benefits and risks of surgery.
Stage 3 Pleural Mesothelioma
Stage 3 mesothelioma is locally or regionally advanced but has not produced distant metastasis.
It is divided into Stage 3A and Stage 3B.
Stage 3A
Stage 3A may include several combinations of tumor and lymph-node involvement.
Examples include:
- A T2 tumor with same-side regional lymph-node involvement
- A T3 tumor with no lymph-node involvement or same-side node involvement
- A T1 through T3 tumor with opposite-side mediastinal or supraclavicular lymph-node involvement
Stage 3A includes several clinically different combinations of local tumor growth and lymph-node involvement. Surgery may be evaluated for a carefully selected minority of patients. Still, its role depends strongly on the exact T and N categories, histological subtype, cardiopulmonary fitness, and review by an experienced multidisciplinary mesothelioma team.
Contralateral mediastinal or supraclavicular lymph-node involvement generally makes surgery less likely to be appropriate, although the final recommendation must be individualized.
Stage 3B
Stage 3B corresponds to a T4 tumor without distant metastasis.
T4 disease has grown into structures that generally prevent complete surgical removal. These may include:
- A chest-wall bone, such as a rib
- Certain mediastinal organs
- The spine
- The opposite pleural surface
- Structures beyond the diaphragm or pericardium
- Tumor involvement associated with malignant pericardial fluid
Regional lymph nodes may or may not be involved.
Symptoms at Stage 3
Local tumor growth may cause more persistent breathlessness, chest pain, cough, fatigue, difficulty swallowing, hoarseness, or reduced activity tolerance. However, these symptoms are not present in every patient and cannot establish the stage without imaging, biopsy findings, and other clinical assessments.
Treatment Planning at Stage 3
Treatment commonly centers on systemic therapy and symptom management.
Depending on the individual case, the care team may discuss:
- Immunotherapy
- Chemotherapy
- Combined systemic regimens
- Radiation therapy for selected symptoms or disease sites
- Procedures to control pleural fluid
- Surgery in a carefully selected subgroup
- Multimodal clinical trials
- Early palliative-care support
Stage 4 Pleural Mesothelioma
Stage 4 is metastatic pleural mesothelioma.
TNM Combination
It is classified as any T, any N, M1.
This means the primary tumor can have any local growth, regional lymph nodes may or may not be involved, and cancer has spread to a distant site.
Possible sites can include:
- Distant lymph nodes
- Bone
- Liver
- The opposite lung or pleural cavity
- The peritoneum
- Other distant organs or tissues
Symptoms at Stage 4
Symptoms may result from the disease in the chest, pleural fluid, reduced general health, or the particular site of distant metastasis. A Stage 4 diagnosis does not predict exactly how long a person will live or how quickly the cancer will progress.
Treatment Planning at Stage 4
Treatment is generally systemic rather than surgical.
Options may include:
- Dual immune-checkpoint inhibition or another guideline-supported immunotherapy regimen
- Platinum-pemetrexed-based chemotherapy, with an additional medication for selected eligible patients
- Chemo-immunotherapy when supported by current clinical recommendations and local regulatory approval
- Clinical trials
- Radiation therapy for pain or control of a specific tumor site
- Drainage of recurrent pleural fluid
- Pleurodesis or placement of an indwelling pleural catheter
- Pain and symptom management
- Nutritional, psychological, rehabilitation, and social support
- Palliative care
The appropriate regimen depends on histological subtype, previous treatment, overall health, organ function, treatment goals, current clinical guidelines, and the availability or approval of specific therapies.
Does Stage 4 Automatically Mean Hospice?
No.
Palliative care and hospice are not the same.
Palliative care can begin at diagnosis and may be given alongside cancer-directed treatment. It helps manage symptoms, treatment side effects, emotional concerns, and practical needs.
Hospice is a form of end-of-life care generally considered when cancer-directed treatment is no longer controlling the disease or is no longer consistent with the patient’s goals.
A Stage 4 diagnosis does not automatically require hospice care.
Early-Stage vs. Advanced Mesothelioma
| Feature | Earlier-Stage Disease | More Advanced Disease |
|---|---|---|
| General extent | More localized to one side of the chest | Greater local invasion, lymph-node involvement, or distant spread |
| Symptoms | May be mild, nonspecific, or significant | May become more persistent or limiting, but vary by person |
| Surgery | May be considered in selected patients | More limited role; generally not used for distant metastatic disease |
| Systemic therapy | May form part of a multimodal plan | Often central to treatment |
| Radiation therapy | May be considered in selected multimodal plans | Often used for local control or symptom relief |
| Palliative care | Can be introduced at any time | Often especially valuable for symptom and quality-of-life support |
| Clinical trials | May be available | May be available and particularly important when standard options are limited |
Do Mesothelioma Symptoms Change by Stage?
Symptoms may become more frequent or limiting as mesothelioma progresses, but no symptom checklist can identify a specific stage.
Pleural effusion can cause substantial breathlessness even when the disease is relatively localized. Tumor location can also influence which symptoms appear first.
Possible pleural mesothelioma symptoms include:
- Shortness of breath
- Chest or back pain
- Persistent cough
- Fatigue
- Hoarseness
- Difficulty swallowing
- Reduced appetite
- Unexplained weight loss
These symptoms have many causes. Imaging and tissue evaluation are required to diagnose and stage mesothelioma.
Symptoms are not a staging tool. Two people with the same stage may experience very different symptoms, and someone with localized disease may have significant breathlessness because of pleural effusion.
Learn more about presentation and evaluation on our mesothelioma symptoms guide.
How Doctors Determine the Stage
Doctors use several tests and procedures to build a complete picture of the disease.
Medical History and Physical Examination
The care team asks about:
- Current symptoms
- Previous asbestos exposure
- Past occupations
- Medical and surgical history
- Smoking history
- Functional ability
- Other illnesses
Physical examination may reveal reduced breath sounds, pleural fluid, weight loss, or other signs needing further evaluation.
CT Scan
A contrast-enhanced CT scan of the chest and upper abdomen is commonly used to assess:
- Pleural thickening
- Tumor distribution
- Pleural fluid
- Chest-wall involvement
- Diaphragm involvement
- Enlarged lymph nodes
- Possible distant disease
CT measurements may also contribute to the current Version 9 tumor classification.
CT is central to staging, but pleural tumor measurements can be technically challenging. Differences in scan technique, tumor shape, pleural fluid, and interpretation may affect measurements. Specialist thoracic radiology review can therefore be valuable.
PET-CT
PET-CT can help identify metabolically active areas that may represent cancer.
It may be useful for evaluating:
- Regional lymph nodes
- Possible distant metastases
- Areas that require biopsy
- Disease that is not clearly characterized on CT alone
Inflammation and infection can also cause PET activity, so results must be interpreted with other findings.
PET-CT findings do not replace biopsy when tissue confirmation is needed. Small tumor deposits may not always be detected, while inflammation or infection can produce false-positive activity.
MRI
MRI provides detailed images of soft tissues.
It may be used when the medical team needs more information about possible involvement of:
- The diaphragm
- The chest wall
- The spine
- Mediastinal structures
- The pericardium
Tissue Biopsy
A tissue biopsy is generally needed to confirm mesothelioma and identify its histological subtype.
The pathologist may classify the tumor as:
- Epithelioid
- Biphasic
- Sarcomatoid
Cell type differs from stage, but it can affect treatment planning and prognosis.
Thoracoscopy
Thoracoscopy allows a specialist to examine the pleural cavity and obtain tissue samples.
It may also provide information about:
- Tumor distribution
- Pleural surfaces
- Diaphragm involvement
- The feasibility of certain procedures
Lymph-Node Assessment
Lymph nodes may be assessed using imaging or biopsy procedures such as:
- Endobronchial ultrasound-guided biopsy
- Endoscopic ultrasound-guided biopsy
- Mediastinoscopy
- Surgical lymph-node sampling
Accurate lymph node assessment may change the stage and treatment plan.
Learn more about the full evaluation process in our mesothelioma diagnosis guide.
Resectable vs. Unresectable Mesothelioma
In addition to the numerical stage, doctors may describe pleural mesothelioma as resectable or unresectable.
Resectable
Resectable generally means that an experienced surgical team believes a macroscopic complete resection—removal of all visible tumor—may be technically achievable with an acceptable level of risk.
This assessment depends on more than the stage. It may include:
- Tumor distribution
- Involvement of vital structures
- Lymph-node status
- Histological subtype
- Heart and lung function
- Performance status
- Surgical expertise
- Patient preferences
Patients with Stage 1, Stage 2, or selected Stage 3A disease may be evaluated for surgery, but stage alone does not establish resectability. Some earlier-stage tumors are not surgically suitable, while a carefully selected patient with more extensive regional disease may still be assessed at a specialist mesothelioma center. The final decision depends on the exact T and N categories, tumor distribution, histological subtype, cardiopulmonary fitness, overall health, and the experience of the multidisciplinary team.
Unresectable
Unresectable means complete removal of visible disease is not technically possible or medically appropriate.
Reasons may include:
- Extensive local invasion
- Distant metastasis
- Tumor location
- Major lymph-node involvement
- Insufficient heart or lung function
- Other serious health conditions
Unresectable does not mean untreatable. Systemic therapy, radiation, symptom-directed procedures, clinical trials, and supportive care may still provide meaningful benefits.
How Stage May Affect Treatment
Stage helps guide treatment planning, but it is not the only deciding factor.
Surgery
Surgery may be discussed for selected people with localized or regionally limited pleural mesothelioma.
Potential operations include lung-sparing and, less commonly, more extensive procedures. Benefits and risks should be reviewed at a center experienced in mesothelioma surgery.
Chemotherapy
Platinum-based chemotherapy with pemetrexed has long been used for mesothelioma.
Chemotherapy may be used:
- Before surgery
- After surgery
- As the main treatment for unresectable disease
- In combination with other treatments
- For recurrent disease
Immunotherapy
Immune checkpoint inhibitors may be used for advanced or unresectable pleural mesothelioma.
The choice of treatment depends on the patient’s diagnosis, previous therapy, cell type, medical condition, and current clinical recommendations.
Radiation Therapy
Radiation therapy may be used:
- As part of a multimodal treatment plan
- To relieve pain
- To control a specific tumor site
- To manage symptoms caused by local growth
Its role depends on disease location and the need to protect nearby organs.
Symptom-Directed Procedures
Procedures may be needed to control pleural fluid and improve breathing.
Examples include:
- Thoracentesis
- Pleurodesis
- Indwelling pleural catheter placement
- Selected surgical procedures
Clinical Trials
Clinical trials evaluate new drugs, treatment combinations, surgical strategies, radiation techniques, biomarkers, and supportive care approaches.
A specialist can help determine whether a trial matches the patient’s stage, cell type, treatment history, and overall condition.
Learn more about the range of options in our mesothelioma treatment options guide.
Staging Other Types of Mesothelioma
The four-stage AJCC TNM system is designed for diffuse pleural mesothelioma.
Other mesothelioma locations are evaluated differently.
Peritoneal Mesothelioma
Peritoneal mesothelioma begins in the lining of the abdomen.
It is not routinely assigned the same AJCC Stage 1–4 classification used for pleural mesothelioma.
Doctors may describe:
- The distribution of disease in the abdomen
- Tumor burden
- Lymph-node involvement
- Distant spread
- Whether complete cytoreduction appears possible
Specialist teams may use the Peritoneal Cancer Index, or PCI, to describe the anatomical distribution and size of tumor deposits across different regions of the abdomen. The score can help characterize disease burden and contribute to surgical assessment. However, PCI is not a direct equivalent of pleural mesothelioma Stage 1, 2, 3, or 4, and it is not a universally accepted AJCC stage grouping for peritoneal mesothelioma.
Pericardial Mesothelioma
Pericardial mesothelioma begins in the tissue surrounding the heart.
Because it is extremely rare, it does not have a widely accepted formal stage-grouping system comparable to the pleural TNM framework.
Doctors instead describe the location, local invasion, and any evidence of distant spread.
Testicular Mesothelioma
Mesothelioma of the tunica vaginalis develops in the lining surrounding the testicle.
It also lacks a widely established AJCC Stage 1–4 system equivalent to that used for diffuse pleural mesothelioma.
Evaluation may focus on local tumor extent, regional lymph nodes, distant spread, pathology findings, and recurrence risk.
Localized Pleural Mesothelioma
Localized pleural mesothelioma is distinct from diffuse pleural mesothelioma.
The AJCC TNM system in this guide was developed for diffuse pleural disease and should not be applied to every localized pleural tumor.
Learn more about how these differ on our types of mesothelioma page.
Stage vs. Grade, Cell Type, and Prognosis
These terms describe different characteristics of mesothelioma. Although they are related, they should not be used interchangeably.
| Term | What It Describes |
|---|---|
| Stage | The anatomical extent of the cancer, including the primary tumor, regional lymph-node involvement, and distant spread |
| Histological grade | A low-grade or high-grade classification used principally for epithelioid diffuse pleural mesothelioma, based on microscopic features including nuclear atypia, mitotic activity, and tumor necrosis |
| Cell type | Whether the mesothelioma is classified as epithelioid, biphasic, or sarcomatoid |
| Resectability | Whether an experienced surgical team believes all visible tumor may be removed with an acceptable level of risk |
| Prognosis | An individualized assessment of the likely course of the disease based on the stage, histology, overall health, treatment response, and other clinical factors |
Histological grade is not applied identically to every mesothelioma subtype. The low-grade and high-grade classification is used principally for epithelioid diffuse pleural mesothelioma. It should not be confused with histological subtype, which classifies mesothelioma as epithelioid, biphasic, or sarcomatoid.
Stage is one of several factors that may influence prognosis. A lower stage generally indicates more localized disease, but it does not guarantee that surgery will be appropriate or that treatment will produce a particular outcome.
Other important prognostic and treatment-planning factors may include:
- Histological subtype
- Histological grade when applicable
- Age
- Performance status
- Overall health
- Heart and lung function
- Blood-test results
- Tumor location and distribution
- Lymph-node involvement
- Whether the tumor is considered resectable
- Response to treatment
- Ability to tolerate treatment
- Previous treatments
- Access to specialist care
- Individual treatment goals and preferences
Published survival statistics describe outcomes among groups of patients treated in previous years. They cannot predict exactly how one individual will respond to treatment or how long that person will live.
Learn more on our mesothelioma prognosis page.
Can the Mesothelioma Stage Change?
The stage assigned at diagnosis usually remains part of the medical record.
After treatment begins, doctors may use new scans and tests to describe:
- Response to treatment
- Stable disease
- Disease progression
- Recurrence
- New metastatic disease
This is sometimes called restaging, but the original stage at diagnosis remains part of the record.
For example, a person initially diagnosed with Stage 2 mesothelioma whose disease later spreads may be described as having recurrent or progressive metastatic mesothelioma rather than receiving an entirely new original stage.
Terminology may vary, so patients should ask their oncologist how changes are documented.
Questions to Ask the Care Team
Consider bringing these questions to an appointment:
- What is the exact stage of my mesothelioma?
- Which edition of the TNM staging system was used?
- Is this a clinical stage or a pathological stage?
- What are my exact T, N, and M categories?
- Has the cancer reached any lymph nodes?
- Is there evidence of distant metastasis?
- Is the tumor considered resectable or unresectable?
- Should my scans or biopsy be reviewed at a mesothelioma center?
- How does my cell type affect the treatment recommendation?
- Do I need additional testing before treatment begins?
- Which treatment options are appropriate for my situation?
- Are there clinical trials I should consider?
- Which symptoms should prompt me to contact the medical team urgently?
- Can I meet a palliative-care specialist while receiving treatment?
- Where can my family and I find emotional, practical, and financial support?
Frequently Asked Questions
How many stages of mesothelioma are there?
Diffuse pleural mesothelioma has four main stages: Stage 1, Stage 2, Stage 3, and Stage 4. Stage 3 is divided into Stage 3A and Stage 3B in the current system.
Which stage of mesothelioma is most treatable?
Stage 1 is the most localized and may offer the widest range of treatment options. However, treatment eligibility depends on more than stage. Tumor location, cell type, overall health, heart and lung function, and resectability also matter.
Can mesothelioma be detected at Stage 1?
Yes, mesothelioma can be diagnosed at Stage 1, but early detection is difficult. Early symptoms are often nonspecific, and there is no widely recommended screening test proven to find mesothelioma early in people without symptoms.
Can symptoms determine the stage?
No. Symptoms may provide clues that further evaluation is needed, but they cannot establish the stage. Imaging, biopsy results, lymph-node assessment, and other tests are required.
Does Stage 4 mesothelioma always mean hospice care?
No. Stage 4 describes distant metastatic disease. Patients may still receive immunotherapy, chemotherapy, radiation therapy, clinical-trial treatment, symptom-directed procedures, and palliative care. Hospice is a separate form of end-of-life care and is not automatically required because of the stage alone.
Is palliative care only for Stage 4 mesothelioma?
No. Palliative care can be offered at any stage and may be provided alongside cancer treatment. It addresses pain, breathing difficulty, fatigue, emotional distress, treatment side effects, and other quality-of-life concerns.
Is peritoneal mesothelioma staged from 1 to 4?
Peritoneal mesothelioma does not routinely use the same AJCC Stage 1–4 system as diffuse pleural mesothelioma. Specialists may instead describe disease distribution using tools such as the Peritoneal Cancer Index.
What is the difference between stage and prognosis?
Stage describes the anatomical extent of the cancer. Prognosis is a broader estimate of the likely disease course based on stage, cell type, overall health, treatment response, and other individual factors.
What is the difference between clinical and pathological staging?
Clinical staging is based on examinations, imaging, biopsy findings, and other tests performed before major surgery. Pathological staging includes information obtained from tissue and findings during an operation.
Can the stage be wrong?
Staging is based on the best information available at the time. Imaging may not detect every small area of disease, and surgery or additional biopsies can sometimes reveal more extensive involvement than initially expected.
When to Seek a Mesothelioma Specialist
Mesothelioma is rare, and staging can be technically complex.
A specialist center may provide:
- Expert pathology review
- Thoracic radiology review
- Multidisciplinary staging
- Surgical assessment
- Access to mesothelioma-focused clinical trials
- Coordinated symptom and supportive care
Seeking a second opinion does not require leaving the original medical team. It can provide valuable information before important treatment decisions.
Summary
Mesothelioma staging describes the amount of cancer present and how far it has spread.
Diffuse pleural mesothelioma is classified from Stage 1 through Stage 4 using the AJCC TNM system. The current Version 9 framework evaluates the primary tumor, regional lymph nodes, and distant metastasis, with updated attention to imaging-based pleural tumor measurements.
Stage 1 is the most localized. Stage 2 reflects greater local extent or limited regional lymph-node involvement. Stage 3 describes more advanced local or regional disease without distant metastasis. Stage 4 means the cancer has spread to a distant site.
Stage is important, but does not determine treatment or prognosis alone. A complete plan should also consider cell type, resectability, overall health, treatment goals, and recommendations from an experienced multidisciplinary team.
Related Mesothelioma Resources
Explore Mesothelioma Stages
More Mesothelioma Resources
References
- American Cancer Society. “Stages of Mesothelioma.” Last revised February 3, 2026. cancer.org.
- American Joint Committee on Cancer. Malignant Pleural Mesothelioma. AJCC Cancer Staging System, Version Nine. American College of Surgeons; 2024. facs.org.
- SEER*RSA. “Pleural Mesothelioma, Version 9: 2025+.” seer.cancer.gov.
- IASLC. Staging Cards in Thoracic Oncology, Ninth Edition. International Association for the Study of Lung Cancer.
- Wolf AS, Eisele M, Giroux DJ, et al. “The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Expanded Database to Inform Revisions in the Ninth Edition of the TNM Classification of Pleural Mesothelioma.” Journal of Thoracic Oncology. 2024;19(8):1242–1252. DOI: 10.1016/j.jtho.2024.01.018.
- National Cancer Institute. Malignant Mesothelioma Treatment—Health Professional Version. cancer.gov.
- Chapel DB, et al. “Updates on Grading Mesothelioma.” Journal of Thoracic Oncology / pathology literature.
- WHO/IASLC pathology review. Histological subtype and grading information. The WHO framework introduced nuclear grading for epithelioid diffuse mesothelioma, while retaining epithelioid, biphasic, and sarcomatoid as the three principal subtypes.
Medical Disclaimer: This article is intended for general educational purposes only. It does not provide medical advice, diagnosis, or treatment and should not replace consultation with a qualified healthcare professional. Treatment and staging decisions must be made by a patient and their medical team based on the individual diagnosis.
